Fosun Pharma and Tiwa reached a strategic cooperation agreement to jointly develop a new cancer immunotherapy drug, the anti-PD1-IL2 therapy.

On June 16th, Fosun Pharma and Teva Pharmaceutical Industries Ltd. jointly announced a strategic collaboration on the development of the investigational drug anti-PD1-IL2 ATTENUKINE therapy TEV-56278 through their respective subsidiaries. According to the agreement, in order to accelerate the development of clinical data, Fosun Pharma will obtain exclusive development, production, and commercialization licenses for TEV-56278 in China and specific Southeast Asian countries. Teva will retain the rights for the development, production, and commercialization of TEV-56278 in other regions worldwide.